The latest news from academia, regulators
research labs and other things of interest
Posted: Aug 25, 2008
NanoViricides Presents EKC, HIV Results, as well as Broad-Spectrum Capability
(Nanowerk News) NanoViricides, Inc. said that Anil R. Diwan, PhD, President of the Company, was a participant in a panel on global pharmaceutical strategies at the Fourth Annual Swedish-American Life Sciences Summit held August 20-22, 2008 in Stockholm, Sweden. Speaking in front of a large pharmaceutical and life sciences finance industry group, he enumerated the accomplishments of the Company. He also presented his thoughts on the Company's global strategy for supplying nanoviricides treatments for serious viral diseases to both developed and developing countries.
Dr. Diwan was invited as a panel member on the panel discussion "Emerging Life Sciences in a Global Context- A New Necessity" held last Friday. After discussing the Company's accomplishments, he spoke about the successes of the nanoviricides technology. In response to a question, he said that the Company has a strong focus on commercially important disease targets such as Influenza, Bird Flu, viral diseases of the eye, HIV, and Hepatitis C. He added that the Company has developed a unique broad-spectrum antiviral technology that can work well against a large number of different viruses. Using such agents, it will be possible to develop cost-effective treatment strategies against lethal diseases of the developing world such as Rabies, Dengue virus, and many others. Many of these diseases are now being seen more frequently in developed countries also.
The Fourth SALSS featured leaders of Life Sciences industry in both Sweden and the United States. This forum brought together key pharmaceutical executives, entrepreneurs, venture capitalists and financiers, and key scientists from both countries in an invitation-only open-discussion format.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.